본문 바로가기

IL-32 gamma suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B

IL-32γ suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B

문서 유형
연구출판물 · 학술지 논문
등재
Nature IndexSCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY146(1) · pp.156 · 2020
피인용
Web of Science 42Scopus 50
FWCI (Scopus)
0
JCR IF
JCR 2019 10.228
ISSN
0091-6749

저자

  1. Lee, Yong Sun제1저자College of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
  2. Han, Sang-BaeCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
  3. Ham, Hyeon JooCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
  4. Park, Ju HoCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
  5. Lee, Jong SungCollege of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea
  6. 황대연Department of Biomaterial Science, College of Natural Resources and Life Science/Life and Industry Convergence Research Institute, Pusan National University, Miryang, Korea
  7. 정영석College of Pharmacy, Pusan National University, Busan, Korea
  8. Yoon, Do Young교신저자Department of Bioscience and Biotechnology, Konkuk University, Seoul, Korea
  9. Hong, Jin Tae교신저자College of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Korea

초록

Background: IL-32 is a novel cytokine involved in many inflammatory diseases. However, the role of IL-32 gamma, an isotype of IL-32, in atopic dermatitis (AD) has not been reported. Objective: We investigated the effects of IL-32 gamma on development of AD and its action mechanisms. Methods: We used phthalic anhydride (PA) and an MC903-induced AD model using wild-type and IL-32 gamma transgenic mice. We conducted the therapy experiments by using recombinant IL-32 gamma protein in a reconstructed human skin model and PA-induced model. We conducted a receiver operating characteristic analysis of IL-32 gamma with new AD biomarkers, IL-31 and IL-33, in serum from patients with AD. Results: Dermatitis severity and epidermal thickness were significantly reduced in PA- and MC903-induced IL-32 gamma transgenic mice compared with in wild-type mice. The concentration of AD-related cytokines was reduced in PA- and MC903-induced IL-32 gamma transgenic mice compared with in wild-type mice. Subsequent analysis showed that IL-32 gamma inhibits miR-205 expression in PA- and MC903-induced skin tissue samples and TNF-alpha/IFN-gamma-treated HaCaT cells. IL-32 gamma reduced NF-kappa B activity in skin tissue samples from PA- and MC903-induced mice and TNF-alpha/IFN-gamma-treated HaCaT cells. NF-kappa B inhibitor treatment with IL-32 gamma expression further suppressed expression of inflammatory mediators as well as miR-205 in TNF-alpha/IFN-gamma-treated HaCaT cells. Furthermore, recombinant IL-32 gamma protein alleviated AD-like inflammation in in vivo and reconstructed human skin models. Spearman correlation analysis showed that serum levels of IL-32 gamma and miR-205 were significantly concordant in patients with AD. Conclusion: Our results indicate that IL-32 gamma reduces AD through the inhibition of miR-205 expression via inactivation of NF-kappa B.

키워드

Atopic dermatitisIL-32 gammamiR-205NF-kappa BTH2 RESPONSESUP-REGULATIONMURINE MODELINFLAMMATIONCELLSACTIVATIONMICRORNASCYTOKINESIL-32IL-1-BETAIL-32γNF-κB

식별자

Scopus EID
2-s2.0-85078898386
WoS UID
000579170500025